























Somatic cells usually undergo a limited number of 
divisions termed the Hayflick limit [1]. When this limit 
is reached, cellular senescence, a permanent cell cycle 
arrest is triggered in conjunction with characteristic 
changes in cell morphology and physiology. Both 
endogenous and exogenous cues such as telomere 
attrition, or stress in the form of oncogene activation or 
DNA damage can induce senescence by activating the 
tumour suppressor p53 [2-4]. Activation of p53 
increases levels of p21
CIP1, which inhibits cyclinE-
CDK2 complexes from phosphorylating the pRB family 
of proteins. This leads to activation of the pRB tumour 
suppressor pathway in which the hypophosphorylated 
pRB family of proteins complex with E2F heterodimers, 
thereby preventing cell cycle progression [2-4]. P21
CIP1 
can also arrest cell cycle progression by inhibiting 
cyclinA/B-CDK1 and cyclinD/CDK4 complexes [5]. 
The pRB pathway can also be activated independently 
of p53 by upregulation of p16
INK4A upon non-genotoxic 
stress, which inhibits cyclinD-CDK4/6 complexes from 
phosphorylating the pRB family of proteins [2-4].  
 
Senescence can dampen the repair and regenerative 
ability of a tissue due to an increased population of 
growth arrested cells and a diminished stem cell 
population; and thereby play a hand in tissue ageing. It 
can also act as a tumour suppressor mechanism by 
preventing the proliferation of potentially cancerous 
cells. Bypass of the cell cycle arrest can lead to  a  limit- 
 
 























less replicative potential, a key step in malignant 
transformation [6]. Blagosklonny has proposed that 
senescence involves two steps:  cell cycle arrest and an 
activation of intracellular signalling pathways which 
result in cellular hypertrophy and a pro-inflammatory 
and hyper-secretory phenotype [7-9]. Although the 
mechanisms underlying the cell cycle arrest are broadly 
known, there remain questions as to what makes the 
growth arrest irreversible, the identity of the critical 
down-stream targets and how the growth arrest is fine 
tuned. It also remains to be determined as to what the 
other intracellular signal transduction pathways 
involved are and how the diverse signals that result in 
senescence are integrated.  
 
The role of nuclear factor (NF)- κB in senescence is 
controversial, as it is divisively associated with 
proliferation and tumour progression, and contrastingly 
with growth arrest and ageing. The NF-κB family of 
transcription factors are ubiquitously expressed and 
regulate the response to cellular and environmental 
stress [10]. In the canonical pathway (Figure 1), homo- 
and heterodimers of these proteins   associate with a 
cytosolic inhibitor, inhibitor of NF-κB (IκB), resulting 
in their retention in the cytoplasm. Phosphorylation of 
IκB by the IκB kinase (IKK) complex (IKKα, IKKβ 
and IKKγ/NEMO) and its subsequent degradation by 

















associated  with  both  proliferation  and  tumour  progression,  and  also  with  growth  arrest  and  ageing.  This  research
perspective focuses on the evidence for a functional relationship between NF‐κB and senescence, and how disruption of
the NF‐κB pathway can lead to its bypass. 
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and induction of target gene transcription [10-14]. The 
canonical pathway is activated by a wide array of 
receptors including those for inflammatory cytokines, 
pathogen-associated molecules and antigen receptors 
and results in the activation of IKKβ [11].  
 
The non-canonical pathway (Figure 1) depends on the 
processing of the p100 precursor protein to produce 
mature p52 (NF-κB2) protein. This involves the NF-κB 
inducing kinase (NIK) phosphorylating and activating 
IKKα, which in turn phosphorylates p100, marking it 
for ubiquitination and proteasomal processing [11].  The 
transactivation potential of NF-κB complexes can be 
further potentiated by direct phosphorylation of RELA, 
for example, by GSK-3β, RSK1 or p38MAPK [15, 16]. 







































Persistent inflammation is an important underlying 
condition that aids tumour development and is 
characterised by the activation of NF-κB signalling. The 
NF-κB family of proteins have been implicated in 
tumour development due to their sequence similarity to 
the viral oncogene v-Rel [17, 18].  Mutations that lead 
to an increase in NF-κB activity have been observed in 
several cancers [17-20], though NF-κB is not believed 
to be required for tumour initiation; it is thought to play 
a role in tumour promotion [20].  NF-κB regulates 
apoptosis genes, with a block in NF-κB leading to an 
increase in apoptosis, suggesting that NF-κB can 
prevent the death of cancer cells [20]. TBK1, a non-
canonical IKK, has been shown to be crucial in the 
context of oncogenic KRAS, by activating anti-
apoptotic signals via NF-κB to aid the survival of 
cancer cells, thus promoting tumour development [21]. 
In addition to the inhibition of apoptosis, NF-κB may 
stimulate other cancer-associated phenotypes [17, 18]. 
In melanoma, NF-κB (RELA-p50) is commonly found 
to be overactive, despite the absence of any reported 
mutations. It can apparently be activated by oncogenic 
BRAF, autocrine cytokines such as TNF, hypoxia via 
HIF1α and AKT (protein kinase B) or oncogenic NRAS 
via AKT. NF-κB has been implicated in invasiveness as 
well as survival, inducing the “epithelial-mesenchymal 
transition” via TWIST1 and SNAI1 [22].  It has also 
been argued that deletion of IKKβ can induce an anti-
tumourigenic phenotype [23], though this may be 
independent of NF-κB as IKKs can also function 
separately of NF-κB signalling. Moreover constitutively 
active IKKβ has been shown to delay Ha-RasV12 
oncogene-induced senescence (OIS) in normal primary 
human fibroblasts by suppressing the DNA damage 
response (DDR), demonstrating that NF-κB activity 
may help to overcome the growth-suppressive effects of 
OIS [24].   
 
In parallel to its role in tumour development, chronic 
inflammation also plays an important role in the ageing 
process.  Increased expression of inflammatory markers 
and an associated increase in NF-κB DNA binding 
activity have been demonstrated in cells from older 
donors over cells from younger donors [25].  This may 
be partly due to the constitutive activation of NF-κB as 
a result of accumulated oxidative stress during ageing, 
which results in persistent inflammation [26]. Adaptive 
immunity also wanes with age placing an extra demand 
on innate immunity, thereby contributing to the 
constitutive activation of NF-κB and chronic 
inflammation [27]. NF-κB has been shown to be 
strongly associated with progeria, a disease of 
premature ageing [28]. Aged tissues exhibit SA β-gal 
activity and enhanced p16
INK4A expression, both of 
 
Figure 1.  Canonical and non‐canonical NFκB signalling





factor  complex.  The  non‐canonical  pathway  is  activated  by  a
more specific set of stimuli such as lymphotoxin β (LT‐β). NIK
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Moreover inhibition of NF-κB in old tissue was shown 
to result in expression of genes characteristic of younger 
tissue [28].   
 
Recently, Rovillain et al. [29] used a novel system of 
conditionally immortal human fibroblasts, which can be 
induced to undergo senescence to show that senescence 
was associated with activation of NF-κB signalling and 
its perturbation by silencing of NF-κB subunits, or by the 
presence of the super repressor of NF-κB (IκB-SR), led 
to the evasion of senescence.  They further showed that 
senescent cells were enriched for the transcriptionally 
active form of  RELA, with phosphorylation at serine 536 
[29].  At the same time, Campisi and colleagues showed 
that increased NF-κB transcriptional activity due to 
p38MAPK activation was sufficient to induce the 
senescence associated secretory phenotype [SASP] of 
senescent fibroblasts [30].  Subsequently, Bertolotto and 
colleagues [31] have shown that a poly (ADP-ribose) 
polymerase-1 (PARP) /NF-κB signalling cascade can 
induce senescence and SASP in melanoma cells.  
 































activated in senescence, a pathway linking genotoxic 
stress to activation of NF-κB (Figure 2) in mouse 
embryo fibroblasts has recently been elucidated by 
Scheidereit and colleagues [32, 33].  They have shown 
that genotoxic stress activates PARP-1 and ataxia 
telangiectasia mutated kinase (ATM) giving rise to 
synthesis of poly ADP-ribose leading to the assembly of 
ATM and an IKKγ, PIASy complex.  This nucleo-
plasmic signalosome triggers PIASy-mediated IKKγ 
sumoylation and IKKγ phosphorylation by ATM. The 
modified IKKγ is then translocated to the cytoplasm and 
integrates into the IKK complex.  The activated ATM is 
also translocated into the cytoplasm, leads to the 
activation of TRAF6 and induces a TRAF6-Ubc13-
mediated polyubiquitin-dependent cascade, resulting in 
TAB2-dependent phosphorylation of TAK1.  Thus both 
PARP-1 and ATM signalling converge to catalyse 
monoubiquitination of IKKγ which is required for 
phosphorylation of IKKγ by TAK1 and enzymatic 
activation of IKK. It remains to be determined if these 
pathways are active in senescence.  However ATM has 
been shown to promote senescence by activating p53 
and suppression of its activity leads to bypass of 














































































Insulin/IGF1 signalling can promote NF-κB signalling 
and potentiate ageing and age-related degeneration by 
activation of the phosphoinositide 3-kinase (PI-3K) 
/AKT pathway (Figure 3) [16]. Although a role for the 
insulin/IGF signalling in human ageing remains 
controversial, this pathway has been conserved in 
evolution from metazoans to mammals and acts via PI-
3K/AKT signalling to maintain cellular homeostasis.  It 
is in this pathway that the functions of FOXO3a and 
SIRT1 (the human homologue of yeast Sir2) intersect 
with NF-κB signalling. FOXO3a is a transcription 
factor that can extend life span and dampen ageing [36]. 
Activation of insulin/IGF1 signalling results in 
phosphorylation of FOXO proteins at a number of sites 
leading to their retention in the cytoplasm [16]. Caloric 
restriction (CR) reduces signalling, leading to FOXOs 
remaining unphosphorylated and being  translocated  to  
the nucleus to enhance the expression of longevity 
genes [37]. AKT phosphorylates FOXO3a, but IKKβ 
can also perform this role [38]. AKT can stimulate NF-
κB signalling by activating the IKK complex by 
phosphorylating IKKβ [16]. AKT itself can be activated 
by loss of the tumour suppressor phosphatase and tensin 
homologue, PTEN, which is one of the most frequently 
altered tumour suppressors in cancer particularly 
prostate cancer [39].  PTEN converts the membrane 
lipid second messenger PIP3 to PIP2, thereby 
inactivating downstream signalling.  Pandolfi and 
colleagues found that loss of PTEN in mice induces 
senescence and that this PTEN-loss-induced-senescence 
is distinct from OIS [40].   
 
CR may also increase expression of SIRT1 (Figure 3), a 
nicotinamide adenosine dinucleotide (NAD) dependent 
deacetylase which binds and deacetylates p65/RELA, 
undoing its acetylation by histone acetyl transferases 
(HATs) and suppressing its transcriptional activity [41]. 
SIRT1 has been found to protect mice from metabolic 
damage and ageing associated diseases such as 
metabolic syndrome, Alzheimer’s disease and some 
types of cancer [42, 43]. Interestingly, Rovillain et al. 
found that in the conditionally immortal human 
fibroblasts, SIRT1 was down-regulated and TMEM9B 
was up-regulated upon senescence  and the differential 
expression was reversed when senescence was bypassed 
[29, 44]. TMEM9B, is a glycosylated lysosomal 
transmembrane protein that can stimulate NF-κB 
activity and acts downstream of receptor interacting 
protein 1 (RIP1) and upstream of MAPK and IκB 
kinases at the level of TAK1 [45, 46].  RIP1 has been 
reported to be the link between the PI-3K/AKT/mTOR 
and NF-κB pathways. It activates signalling 
downstream of PI-3K/AKT by down-regulating PTEN 
and interrupting the negative feedback loop that extends 
from mTOR to PI-3K/AKT by inhibiting mTOR via 
NF-κB [47, 48].   
 
FOXM1 is a highly conserved forkhead transcription 
factor that regulates the expression of numerous 
regulators of cell cycle progression, particularly in the 
G2 phase [49]. FOXM1 is down-regulated upon 
replicative senescence [50] and also markedly reduced 
in cells from elderly patients as well as those with 
progeria [51]. Marcu and colleagues have shown that 
acute activation of NF-κB in mouse embryo fibroblasts 
leads to growth arrest in association with repression of 
FoxM1 and cell cycle regulated genes that are known 
targets of E2F or FOXM1 [52]. Rovillain et al. [29] 
found that FOXM1 was downregulated upon 
senescence in the conditionally immortal fibroblasts and 
that a constitutively active FOXM1 bypasses 
 
Figure  3.  A  schematic  illustration  of  the  pathways
linking  caloric  restriction,  Insulin/IGF,  PI‐3K/AKT  and 
NF‐κB  signalling  (adapted  from  Salminen  and
Kaarniranta  [16]  and  Chauncey  et  al.  [48]).  Sustained 
insulin/IGF signalling promotes NF‐κB signalling by activation
of PI‐3K/AKT pathway whereas caloric restriction (CR) reduces
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may induce senescence by repressing FOXM1.  
 
Senescent cells secrete growth factors, proteases, and 
inflammatory cytokines as part of the SASP [53-60]. 
Despite the ability of these factors to promote a 
malignant phenotype in a paracrine manner, SASP 
components can bolster senescence in an autocrine 
manner [53-60], and some even promote the clearance 
of senescent cells by the immune system [61]. SASP 
can thus be stimulatory or inhibitory for tumourogenesis 
depending on the biological context, with it possibly 
promoting tumourigenesis in aged tissues [30, 59, 60]. 
The stress-activated kinase p38 has been shown to 
regulate SASP; inhibition supresses SASP secretion, 
whereas constitutive activation is sufficient for 
induction. The effect of p38MAPK on SASP is 
mediated by increased transcriptional activity of NF-κB 
[30]; p38MAPK has also been suggested to inhibit 
FoxM1 expression [62]. 
 
In this perspective, we have reviewed the recent 
findings about the role of NF-κB signalling in ageing 
and senescence, and weighed up the contradictory 
evidence. Previous studies had proposed NF-κB 
signalling as a proliferative message, as well as others 
conversely implicating NF-κB signalling in growth 
arrest.  With such controversy, many questions remain 
to be answered.  Our latest results show that silencing of 
NF-κB allowed cells to bypass senescence, and that 
activation of NF-κB signalling leads to upregulation of 
genes associated with SASP [29] and suppression of 
FOXM1 and other cell cycle progression genes.  Based 
on these findings and others discussed here, we propose 
that activation of NF-κB signalling, in normal somatic 
cells, promotes senescence and by extension acts to 
enhance ageing. A better understanding of the role of 
NF-κB signalling and how it gets activated will increase 
our knowledge of the pathobiology of ageing and age 
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